Cargando…

Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)

Background: Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based on the discovery of new immunotherapy and targeted therapy drugs. However, chemotherapy is still an option...

Descripción completa

Detalles Bibliográficos
Autores principales: Assi, Hazem I., Zerdan, Maroun Bou, Hodroj, Mohammad, Khoury, Makram, Naji, Nour Sabiha, Amhaz, Ghid, Zeidane, Reine Abou, El Karak, Fadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219655/
https://www.ncbi.nlm.nih.gov/pubmed/37235814
http://dx.doi.org/10.18632/oncotarget.28444
_version_ 1785049060246290432
author Assi, Hazem I.
Zerdan, Maroun Bou
Hodroj, Mohammad
Khoury, Makram
Naji, Nour Sabiha
Amhaz, Ghid
Zeidane, Reine Abou
El Karak, Fadi
author_facet Assi, Hazem I.
Zerdan, Maroun Bou
Hodroj, Mohammad
Khoury, Makram
Naji, Nour Sabiha
Amhaz, Ghid
Zeidane, Reine Abou
El Karak, Fadi
author_sort Assi, Hazem I.
collection PubMed
description Background: Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based on the discovery of new immunotherapy and targeted therapy drugs. However, chemotherapy is still an option for treatment of advanced non-small cell lung cancer (NSCLC) after progression on immunotherapy alone or in combination with first-line chemotherapy. Methods: This is a retrospective study based on chart review of patients diagnosed with advanced NSCLC cases who received Docetaxel as second or third line after being treated by immunotherapy and/or chemotherapy in previous lines. The data was collected from the medical records of physicians’ clinics in three different hospital centers in Lebanon over the period of 5 years from July 2015 until December 2020. February 2021 was data analysis cut off time. The main aim was to assess the role of Docetaxel post-chemoimmunotherapy for patients with diagnosed NSCLC. Results: A total of 21 patients were included in this study. The majority of our patients were males (81%). As for histologic type, most patients had non-squamous lung cancer (67%) as compared to 33% who had squamous lung cancer. Overall, our study reported a 24% response rate to Docetaxel including stable disease and partial response and a median progression free survival (PFS) of 3 months. The mean time interval elapsed from diagnosis to the initiation of Docetaxel was 11.5 months. Conclusion: New therapeutic options should be validated for the treatment of NSCLC in the second and subsequent lines of therapy considering the poor prognosis of this disease. The chemotherapy in second and third line may keep an important role in the treatment after progression on newer agents, but it needs more evidence in prospective studies including a larger number of patients.
format Online
Article
Text
id pubmed-10219655
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-102196552023-05-27 Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC) Assi, Hazem I. Zerdan, Maroun Bou Hodroj, Mohammad Khoury, Makram Naji, Nour Sabiha Amhaz, Ghid Zeidane, Reine Abou El Karak, Fadi Oncotarget Research Paper Background: Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its treatment landscape has shifted from the classic chemotherapy alone to newer regimens based on the discovery of new immunotherapy and targeted therapy drugs. However, chemotherapy is still an option for treatment of advanced non-small cell lung cancer (NSCLC) after progression on immunotherapy alone or in combination with first-line chemotherapy. Methods: This is a retrospective study based on chart review of patients diagnosed with advanced NSCLC cases who received Docetaxel as second or third line after being treated by immunotherapy and/or chemotherapy in previous lines. The data was collected from the medical records of physicians’ clinics in three different hospital centers in Lebanon over the period of 5 years from July 2015 until December 2020. February 2021 was data analysis cut off time. The main aim was to assess the role of Docetaxel post-chemoimmunotherapy for patients with diagnosed NSCLC. Results: A total of 21 patients were included in this study. The majority of our patients were males (81%). As for histologic type, most patients had non-squamous lung cancer (67%) as compared to 33% who had squamous lung cancer. Overall, our study reported a 24% response rate to Docetaxel including stable disease and partial response and a median progression free survival (PFS) of 3 months. The mean time interval elapsed from diagnosis to the initiation of Docetaxel was 11.5 months. Conclusion: New therapeutic options should be validated for the treatment of NSCLC in the second and subsequent lines of therapy considering the poor prognosis of this disease. The chemotherapy in second and third line may keep an important role in the treatment after progression on newer agents, but it needs more evidence in prospective studies including a larger number of patients. Impact Journals LLC 2023-05-26 /pmc/articles/PMC10219655/ /pubmed/37235814 http://dx.doi.org/10.18632/oncotarget.28444 Text en Copyright: © 2023 Assi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Assi, Hazem I.
Zerdan, Maroun Bou
Hodroj, Mohammad
Khoury, Makram
Naji, Nour Sabiha
Amhaz, Ghid
Zeidane, Reine Abou
El Karak, Fadi
Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
title Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
title_full Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
title_fullStr Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
title_full_unstemmed Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
title_short Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
title_sort value of chemotherapy post immunotherapy in stage iv non-small cell lung cancer (nsclc)
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219655/
https://www.ncbi.nlm.nih.gov/pubmed/37235814
http://dx.doi.org/10.18632/oncotarget.28444
work_keys_str_mv AT assihazemi valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT zerdanmarounbou valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT hodrojmohammad valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT khourymakram valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT najinoursabiha valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT amhazghid valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT zeidanereineabou valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc
AT elkarakfadi valueofchemotherapypostimmunotherapyinstageivnonsmallcelllungcancernsclc